With $22M B round, OncoCell to launch prostate cancer test

With its $22.2 million series B round, OncoCell plans to launch next summer the first blood test from its diagnostic platform based on immune gene expression profiles.

Mark McDonough, president and CEO of OncoCell Mdx Inc. (Corvallis, Ore.), told BioCentury the company’s platform can detect multiple types of cancer and autoimmune, cardiovascular and neurodegenerative diseases, as well as disease stages, from a single blood draw...